Compare ALPS & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ALPS | ELOX |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 60.3M |
| IPO Year | 2024 | 2013 |
| Metric | ALPS | ELOX |
|---|---|---|
| Price | $0.32 | $12.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 31.0K | 21.5K |
| Earning Date | 07-24-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $10.00 |
| 52 Week High | $1.72 | $23.40 |
| Indicator | ALPS | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 42.34 |
| Support Level | $0.23 | $10.74 |
| Resistance Level | $0.42 | $14.65 |
| Average True Range (ATR) | 0.01 | 1.10 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 10.90 | 45.09 |
ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.